RT Journal Article
SR Electronic
T1 INOVASIA Study: A Randomized Open Controlled Trial to Evaluate Prophylactic Pravastatin in the Prevention of Preeclampsia and its Effects on sFlt1/PLGF Levels in Pregnant Women at High Risk of Developing Preeclampsia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.19.21259184
DO 10.1101/2021.06.19.21259184
A1 Aldika Akbar, Muhammad Ilham
A1 Yosediputra, Angelina
A1 Pratama, Raditya Eri
A1 Fadhilah, Nur Lailatul
A1 Sulistyowati
A1 Amani, Fariska Zata
A1 Ernawati
A1 Dachlan, Erry Gumilar
A1 Angsar, Muhammad Dikman
A1 Dekker, Gus
YR 2021
UL http://medrxiv.org/content/early/2021/06/21/2021.06.19.21259184.abstract
AB Objectives The study aim is to evaluate the effect of pravastatin to prevent preeclampsia (PE) in pregnant women at a high risk of developing preeclampsia and the maternal and perinatal outcomes and the sFlt1/PLGF ratio in the Surabaya cohort of the INOVASIA trial.Setting This study involved 2 academic hospital (a tertiary and secondary center) in Surabaya, Indonesia.Participants Pregnant women at a high risk of developing PE were recruited and randomized into an intervention group (40) and a control group (40). The inclusion criteria consisted of pregnant women with positive clinical risk factor and abnormal uterine artery doppler examination at 10-20 weeks gestational age.Inteventions The control group received low dose aspirin (80 mg/day) and calcium (1 g/day), while the intervention group received additional pravastatin (20 mg twice daily) starting from 14-20 weeks gestation until delivery. Research blood samples were collected before the first dose of pravastatin, and just before delivery.Primary and Secondary Outcomes The primary outcome was the rate of maternal preeclampsia, secondary outcomes included maternal-perinatal outcomes and sFlt-1, PLGF, sFlt-1/PlGF ratio and sEng levels.Results The rate of preeclampsia was (non-significantly) lower in the pravastatin group compared with the control group (17.5% vs 35%). The pravastatin group also had a (non-significant) lower rate of severe preeclampsia, HELLP syndrome, acute kidney injury and severe hypertension. The rate of (iatrogenic) preterm delivery was significantly lower (p 0.048) in the pravastatin group (n=4) compared with the controls (n=12). Neonates in the pravastatin group had significantly higher birthweights, higher Apgar scores, and lower composite neonatal morbidity and NICU admission rates. All biomarkers show a significant deterioration in the control group compared with non-significant changes in the pravastatin group.Conclusions Pravastatin holds promise in the secondary prevention of preeclampsia and placenta-mediated adverse perinatal outcomes by improving the anti-angiogenic/pro-angiogenic imbalance.Trial Registration Clinical Trial Gov (ID: NCT03648970)Strengths and limitations of this studyThe largest randomized clinical trial reporting the effects of pravastatin in the prevention of preeclampsia in pregnant women at a high risk of developing preeclampsia with maternal preeclampsia as primary endpointSecondary outpoints included perinatal outcomes, and sFlt-1, PlGF, sFlt-1/PlGF ratio, and sEng levelsInsufficient funding for placebo tables in the setting of Indonesia, a developing country, resulted in the trial design being an open randomized controlled trialIn order to reduce risk of bias, 2 independent MFM consultants evaluated and verified all abnormal outcomes while being blinded for group allocation of the trial participantsCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03648970Funding StatementNot applicableAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The INOVASIA study was approved by the Ethical and Law Committee of Universitas Airlangga Academic Hospital (122/KEH/2017) and The Ethical Committee in Health Research Dr. Soetomo General Academic Hospital Surabaya (427/Panke.KKE/VII/2017)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data of this study are available from Universitas Airlangga Hospital and Dr. Soetomo General Hospital but restrictions apply to the availability of these data and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Universitas Airlangga Hospital and Dr. Soetomo General Hospital.